Literature DB >> 11906465

Nitric oxide-mediated vasodilatory effect of atrial natriuretic peptide in forearm vessels of healthy humans.

Takashi Sugamori1, Yutaka Ishibashi, Toshio Shimada, Takeshi Sakane, Nobuyuki Takahashi, Shuzo Ohata, Nobuhiro Kodani, Yoshitsugu Kunizawa, Shin-ichi Inoue, Yoko Ohta, Ko Nakamura, Hiromi Shimizu, Harumi Katoh, Yo Murakami.   

Abstract

1. The aim of the present study was to determine whether the vasorelaxant effect of atrial natriuretic peptide (ANP) is, in part, endothelium dependent in humans. 2. We used veno-occlusive plethysmography to measure forearm blood flow (FBF) during intra-arterial infusions of ANP (4, 8, 16, 32 pmol/min per dL forearm tissue volume) before and after the inhibition of nitric oxide (NO) synthesis by N(G)-monomethyl-L-arginine (L-NMMA; 100 micromol) in seven normal healthy subjects. 3. Atrial natriuretic peptide caused a dose-dependent increase in FBF both before and after L-NMMA and significantly reduced the plasma concentration of angiotensin (Ang) II. Administration of L-NMMA significantly diminished the increase in FBF in response to ANP infusion (P < 0.05). 4. These results suggest that the forearm vasodilative response to ANP is modulated, in part, by an endothelium-derived NO-mediated mechanism associated with a decrease in AngII caused by ANP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906465     DOI: 10.1046/j.1440-1681.2002.03597.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  2 in total

1.  Reciprocal regulation of human soluble and particulate guanylate cyclases in vivo.

Authors:  M Madhani; M Okorie; A J Hobbs; R J MacAllister
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

Review 2.  The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases.

Authors:  Angelino Calderone
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.